As more people lose weight using medications like Ozempic, Wegovy and Mounjaro, food companies ramp up their efforts to keep ...

New research indicates GLP1-RA medications do not increase thyroid cancer risk, reassuring users and clinicians. A new study, ...

Managing diabetes and chronic lymphocytic leukemia is challenging, but with proactive care, mindfulness and diet changes, I'm ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

For more information, see these articles on Wegovy’s dosage and Zepbound’s dosage. Ozempic and Trulicity belong to the same group of drugs, called glucagon-like peptide-1 (GLP-1) receptor ...

But Lilly and Novo Nordisk continue to welcome that challenge — their head-to-head battles began in 2012 with Lilly’s once-weekly injectable Trulicity ... Mounjaro at a dose of 5 mg, 10 ...

The new oral drug is viewed as a key product for Novo Nordisk as it tries to case Eli Lilly's Trulicity (dulaglutide ... Vaxchora will be the only single-dose oral vaccine indicated for active ...

GLP-1 receptor agonists, originally introduced in 2006, have undergone significant advancements over the years. David Ricks, ...

The prescribed dosage for Vraylar (cariprazine) may depend on a person’s individual treatment plan. Factors like your medical history and other medications you may be taking can affect your ...

Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...